These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 11838592)

  • 21. Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis.
    Stegeman CA
    Nephrol Dial Transplant; 2002 Dec; 17(12):2077-80. PubMed ID: 12454214
    [No Abstract]   [Full Text] [Related]  

  • 22. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group.
    Jayne DR; Rasmussen N
    Mayo Clin Proc; 1997 Aug; 72(8):737-47. PubMed ID: 9276602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vasculitis syndromes: which maintenance therapy for ANCA vasculitis?
    Nachman PH
    Nat Rev Nephrol; 2009 May; 5(5):254-6. PubMed ID: 19384325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of acute c-ANCA-positive vasculitis with mycophenolate mofetil.
    Waiser J; Budde K; Braasch E; Neumayer HH
    Am J Kidney Dis; 1999 Sep; 34(3):e9. PubMed ID: 10471756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil versus cyclophosphamide for inducing remission of ANCA vasculitis with moderate renal involvement.
    Hu W; Liu C; Xie H; Chen H; Liu Z; Li L
    Nephrol Dial Transplant; 2008 Apr; 23(4):1307-12. PubMed ID: 18065810
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
    Holle JU; Gross WL
    J Autoimmun; 2009; 32(3-4):163-71. PubMed ID: 19345067
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New treatments of ANCA-associated vasculitis.
    Kallenberg CG; Tervaert JW
    Sarcoidosis Vasc Diffuse Lung Dis; 2000 Jun; 17(2):125-9. PubMed ID: 10957760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complexed plasma elastase as an in vivo marker for leukocyte activation in antineutrophil cytoplasmic antibody-associated vasculitis.
    Haubitz M; Schulzeck P; Schellong S; Schulze M; Koch KM; Brunkhorst R
    Arthritis Rheum; 1997 Sep; 40(9):1680-4. PubMed ID: 9324023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ANCA testing in monitoring the activity of the disease.
    Tervaert JW
    Kidney Blood Press Res; 2003; 26(4):226-30. PubMed ID: 14504422
    [No Abstract]   [Full Text] [Related]  

  • 30. A child with panniculitis and microhaematuria/proteinuria--an unusual presentation of p-ANCA-positive vasculitis.
    Korzets Z; Pomeranz A; Bernheim J; Lazarov A; Wolach B; Bernheim J
    Nephrol Dial Transplant; 1997 Apr; 12(4):787-9. PubMed ID: 9141014
    [No Abstract]   [Full Text] [Related]  

  • 31. The crucial role of renal biopsy in the management of ANCA-associated renal vasculitis.
    Ferrario F; Rastaldi MP; D'Amico G
    Nephrol Dial Transplant; 1996 Apr; 11(4):726-8. PubMed ID: 8671873
    [No Abstract]   [Full Text] [Related]  

  • 32. Cogan's syndrome and development of ANCA-associated renal vasculitis after lengthy disease remission.
    Lydon EJ; Barisoni L; Belmont HM
    Clin Exp Rheumatol; 2009; 27(1 Suppl 52):S144. PubMed ID: 19646364
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of ANCA associated systemic necrotizing vasculitides].
    Guillevin L
    Bull Acad Natl Med; 2008; 192(6):1175-87; discussion 1188. PubMed ID: 19235481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinicopathological characteristics of propylthiouracil-induced antineutrophil cytoplasmic antibodies-positive vasculitis and their target antigens: a report of 4 cases and literature review].
    Xu X; Zhao M; Zhang Y; Guo X; Wang H
    Zhonghua Nei Ke Za Zhi; 2002 Jun; 41(6):404-7. PubMed ID: 12137604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pulmonary vasculitis.
    Burns A
    Br J Hosp Med; 1997 Oct 15-Nov 4; 58(8):389-92. PubMed ID: 9509040
    [No Abstract]   [Full Text] [Related]  

  • 36. ANCA-associated vasculitis: new options beyond steroids and cytotoxic drugs.
    Selamet U; Kovaliv YB; Savage CO; Harper L
    Expert Opin Investig Drugs; 2007 May; 16(5):689-703. PubMed ID: 17461741
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment.
    Sanders JS; Huitma MG; Kallenberg CG; Stegeman CA
    Rheumatology (Oxford); 2006 Jun; 45(6):724-9. PubMed ID: 16399845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [What's new in systemic vasculitis?].
    Müller A; Csernok E
    Z Rheumatol; 2002 Oct; 61(5):610-2. PubMed ID: 12399893
    [No Abstract]   [Full Text] [Related]  

  • 39. Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force.
    Mukhtyar C; Flossmann O; Hellmich B; Bacon P; Cid M; Cohen-Tervaert JW; Gross WL; Guillevin L; Jayne D; Mahr A; Merkel PA; Raspe H; Scott D; Witter J; Yazici H; Luqmani RA;
    Ann Rheum Dis; 2008 Jul; 67(7):1004-10. PubMed ID: 17911225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ANCA-positive vasculitis.
    Kamesh L; Harper L; Savage CO
    J Am Soc Nephrol; 2002 Jul; 13(7):1953-60. PubMed ID: 12089393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.